ADA 2023 – Toxicity undermines Boehringer and Zealand’s incretin
A quarter of patients fail to stomach survodutide.
Zealand seeks deals in obesity and beyond
With Boehringer locked in, the Danish biotech wants more partners for monotherapies, combos and more.
Boehringer signals intent in obesity
Obesity is biopharma’s hottest ticket, and Boehringer Ingelheim wants a seat at the show.
Silicon Valley Bank: biopharma’s latest crisis
Hopes are high that a buyer will emerge, but the fast-moving downfall of a big name in biopharma banking is not over yet.
Fourth-quarter data for the little guys
Relmada, Albireo and Mirum prepare for important clinical results, as Intercept is set back again.